Nasdaq
$1.47▼ 2.33%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.4MShares out 3.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 10.15Regular26.10.16 01:31SCHEDULE 13GOwnership#●●●
FEMASYS INC
Empery Asset Management, LP and Ryan M. Lane have entered into a joint filing agreement for the Schedule 13G statement regarding Femasys Inc. The agreement, dated October 15, 2026, establishes their commitment to coordinate future filings and maintain the accuracy of their reported ownership information.…more
$1.47-2.33%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.29Pre-market26.09.29 20:02424B3Offering
FEMASYS INC
Femasys Inc. has filed for the resale of up to 28,124,997 shares of common stock related to a private placement completed on August 10, 2026. This registration covers shares issuable upon the exercise of pre-funded, common, and milestone warrants, and the company will not receive proceeds from the resale except upon warrant exercise. Additionally, the company is defending against a lawsuit filed by Iroquois Capital seeking approximately $3.1 million in repayment related to convertible notes issued in November 2025.…more
$1.47-2.33%vs prev closeView filingShare - 9.29Pre-market26.09.29 13:15filedEFFECTOther
FEMASYS INC
Femasys Inc. received SEC effectiveness for its registration statement on September 28, 2026. This filing confirms that the company has completed the necessary legal procedures to proceed with the issuance of new securities and capital raising.…more
$1.47-2.33%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.20 22:00#●●●#●●●
Femasys Partners with SandsRx Pharmacy to Support FemaSeed Fertility Portfolio Launch…more
Femasys has entered into a partnership with SandsRx Pharmacy to provide specialized medication support and pricing for its FemaSeed fertility product line. While this collaboration aims to improve accessibility for OB/GYN practices, it does not disclose specific financial impacts or revenue targets.…more
$1.47-2.33%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.14Pre-market26.10.14 22:01
●●●●●●●● ●●●●● ●●●●●●
Femasys has doubled the number of active clinical trial sites for its FemBloc permanent birth control study to twelve across the U.S. The inclusion of prominent academic centers highlights growing clinical interest and progress in the company's pivotal trial program.…more
$1.47-2.33%vs prev closeShareBenzinga - 10.8Pre-market26.10.08 22:00
●●●●●●●● ●●●●● ●●●●●●
Femasys announced its participation in the ASRM 2026 Scientific Congress to showcase its fertility treatment and diagnostic portfolio. This exhibition is a marketing effort to increase product awareness and does not represent a new commercial contract or financial milestone.…more
$1.47-2.33%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report